Fly News Breaks for August 2, 2019
ADAP
Aug 2, 2019 | 07:13 EDT
As previously reported, Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy as he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. Additionally, financing needs may be an overhang, said Schmidt. While results to date for MAGE-A4 in synovial sarcoma "look intriguing," its commercial opportunity is small, added Schmidt.
News For ADAP From the Last 2 Days
There are no results for your query ADAP